SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
LAUKIEN FRANK H

(Last) (First) (Middle)

(Street)

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BRUKER AXS INC [ BAXS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
CEO, President
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2003
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2003 D 7,467,965 D 0(1) 0(1) D
Common Stock 07/01/2003 D 292,535 D 0(2) 0(2) I By former wife. Filer retained voting rights.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) 1.76 07/01/2003 D 50,000 04/28/2003(3) 04/28/2010 Common Stock 50,000 $1.76(3) 0 D
Stock Option (right to buy) 2.1 07/01/2003 D 10,000 05/07/2003(4) 05/07/2012 Common Stock 10,000 $2.1(4) 0 D
Stock Option (right to buy) 2.26 07/01/2003 D 10,000 05/07/2004(5) 05/07/2013 Common Stock 10,000 $2.26(5) 0 D
Explanation of Responses:
1. Disposed of in exchange for 4,704,818 shares of Bruker BioSciences Corporation common stock in connection with the merger of Bruker AXS Inc. into Bruker Daltonics Inc., now known as Bruker BioSciences Corporation (the "Merger"). On the effective date of the Merger, the closing price of Bruker Daltonics Inc.'s common stock was $5.50 per share, and the closing price of Bruker AXS Inc. was $3.38 per share.
2. Disposed of in exchange for 184,297 shares of Bruker BioSciences Coroporation common stock in connection with the merger of Bruker AXS Inc. into Bruker Daltonics Inc., now known as Bruker BioSciences Corporation (the "Merger"). On the effective date of the Merger, the closing price of Bruker Daltonics Inc.'s common stock was $5.50 per share, and the closing price of Bruker AXS Inc. was $3.38 per share.
3. In connection with the Merger, filer's option to receive 50,000 shares of Bruker AXS Inc. common stock was converted into an option to purchase 31,500 shares of Bruker BioSciences Corporation common stock at a price of $2.79 per share.
4. In connection with the Merger, filer's option to receive 10,000 shares of Bruker AXS Inc. common stock was converted into an option to purchase 6,300 shares of Bruker BioSciences Corporation common stock at a price of $3.33 per share.
5. In connection with the Merger, filer's option to receive 10,000 shares of Bruker AXS Inc. common stock was converted into an option to purchase 6,300 shares of Bruker BioSciences Corporation common stock at a price of $3.59 per share.
Frank H. Laukien 07/01/2003
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.